Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications

Neurology

Volumn 48, Issue 2, 1997, Pages 369-372

  Verhagen Metman, L ^a   Locatelli, E R ^a   Bravi, D ^a   Mouradian, M M ^a   Chase, T N ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; LEVODOPA;

ADULT; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; HUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0343329775     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.48.2.369     Document Type: Article

References (18)

1. Mouradian MM, Chase TN. Central mechanisms and levodopa response fluctuations in Parkinson's disease. Clin Neuropharmacol 1988;11:378-385.
2. Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 1994;44(suppl 6): S15-18.
3. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994;662:69-74.
4. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994; 36:27-31.
5. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms. Part II. Ann Neurol 1988;24: 372-378.
6. Davis TL, Brughitta G, Baronti F, Mouradian MM. Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology 1991;41:630-633.
7. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol 1996;69:497-501.
8. Di Chiara G, Gessa GL. Pharmacology and neurochemistry of apomorphine. Adv Pharmacol Chemother 1978;15:87-160.
9. Mouradian MM, Chase TN. Central mechanisms and levodopa response fluctuations in Parkinson's disease. Clin Neuropharmacol 1988;11:378-385.
10. Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25:523-526.
11. Kotter R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog Neurobiol 1994;44:163-196.
12. Cepeda C, Buchwald NA, Levine MS. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci USA 1993;90:9576-9580.
13. Marin C, Papa SM, Engber TM, Bonastre M, Tolosa E, Chase TN. MK801 prevents levodopa-induced motor response alterations in parkinsonian rats [abstract]. Mov Disord 1996; 11(suppl 1):126.
14. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994;5:2586-2588.
15. Papa SM, Chase TN. Levodopa induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-578.
16. Blanchet PJ, Verhagen Metman L, Mouradian MM, Chase TN. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov Disord 1996;11:580-581.
17. Verhagen Metman L, Blanchet PJ, Mouradian MM, Chase TN. Dextromethorphan and levodopa combination therapy in parkinsonian patients with response fluctuations [abstract]. Mov Disord 1996;11(suppl 1):184.
18. Standaert DG, Testa CM, Young AB, Penney JJ. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J Comp Neurol 1994;343:1-16.